273 related articles for article (PubMed ID: 35690574)
1. Discordance in the reduction rate between glycated albumin and glycated hemoglobin levels in type 2 diabetes patients receiving SGLT2 inhibitors.
Shimizu N; Ogawa A; Hayashi A; Shichiri M
J Diabetes Complications; 2022 Jul; 36(7):108225. PubMed ID: 35690574
[TBL] [Abstract][Full Text] [Related]
2. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.
Shao SC; Chang KC; Lin SJ; Chien RN; Hung MJ; Chan YY; Kao Yang YH; Lai EC
Cardiovasc Diabetol; 2020 Feb; 19(1):17. PubMed ID: 32050968
[TBL] [Abstract][Full Text] [Related]
3. Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors.
Lee JY; Cho Y; Lee M; Kim YJ; Lee YH; Lee BW; Cha BS; Kang ES
Diabetes Metab J; 2019 Apr; 43(2):158-173. PubMed ID: 30688052
[TBL] [Abstract][Full Text] [Related]
4. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Lingvay I
Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
[TBL] [Abstract][Full Text] [Related]
5. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.
Scheen AJ
Diabetes Metab; 2020 Jun; 46(3):186-196. PubMed ID: 32007623
[TBL] [Abstract][Full Text] [Related]
6. Glycated albumin (GA) is more advantageous than hemoglobin A1c for evaluating the efficacy of sitagliptin in achieving glycemic control in patients with type 2 diabetes.
Shima K; Komatsu M; Noma Y; Miya K
Intern Med; 2014; 53(8):829-35. PubMed ID: 24739602
[TBL] [Abstract][Full Text] [Related]
7. Combination of sodium-glucose cotransporter 2 inhibitor and dipeptidyl peptidase-4 inhibitor in type 2 diabetes: a systematic review with meta-analysis.
Min SH; Yoon JH; Moon SJ; Hahn S; Cho YM
Sci Rep; 2018 Mar; 8(1):4466. PubMed ID: 29535389
[TBL] [Abstract][Full Text] [Related]
8. Effects of Concomitant Administration of a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Showing Relatively Good Glycemic Control Under Treatment with a Sodium Glucose Co-Transporter 2 Inhibitor.
Kusunoki M; Natsume Y; Miyata T; Tsutsumi K; Oshida Y
Drug Res (Stuttg); 2018 Dec; 68(12):704-709. PubMed ID: 29966149
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
[TBL] [Abstract][Full Text] [Related]
10. The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor.
Feng X; Gu Q; Gao G; Yuan L; Li Q; Zhang Y
Ann Endocrinol (Paris); 2020 Oct; 81(5):476-481. PubMed ID: 32822653
[TBL] [Abstract][Full Text] [Related]
11. Predictors for the Treatment Effect of Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
Yagi S; Aihara KI; Kondo T; Kurahashi K; Yoshida S; Endo I; Fukuda D; Nakaya Y; Suwaki KI; Takeji T; Wada T; Salim HM; Hama S; Matsuura T; Ise T; Kusunose K; Yamaguchi K; Tobiume T; Yamada H; Soeki T; Wakatsuki T; Matsuhisa M; Shimabukuro M; Akaike M; Sata M
Adv Ther; 2018 Jan; 35(1):124-134. PubMed ID: 29185199
[TBL] [Abstract][Full Text] [Related]
12. Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study.
Dennis JM; Young KG; McGovern AP; Mateen BA; Vollmer SJ; Simpson MD; Henley WE; Holman RR; Sattar N; Pearson ER; Hattersley AT; Jones AG; Shields BM;
Lancet Digit Health; 2022 Dec; 4(12):e873-e883. PubMed ID: 36427949
[TBL] [Abstract][Full Text] [Related]
13. Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial.
Goldenberg RM
Clin Ther; 2017 Dec; 39(12):2438-2447. PubMed ID: 29174215
[TBL] [Abstract][Full Text] [Related]
14. Glycated albumin is superior to glycated hemoglobin for glycemic control assessment at an early stage of diabetes treatment: A multicenter, prospective study.
Lu JM; Ji LN; Li YF; Li QM; Lin SS; Lv XF; Wang L; Xu Y; Guo XH; Guo QY; Ma L; Du J; Chen YL; Zhao CL; Zhang QL; She QM; Jiao XM; Lu MH; Pan RQ; Gao Y
J Diabetes Complications; 2016; 30(8):1609-1613. PubMed ID: 27496253
[TBL] [Abstract][Full Text] [Related]
15. Distinct biomarker roles for HbA
Hayashi A; Takano K; Masaki T; Yoshino S; Ogawa A; Shichiri M
J Diabetes Complications; 2016; 30(8):1494-1499. PubMed ID: 27614726
[TBL] [Abstract][Full Text] [Related]
16. Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study.
Fushimi Y; Obata A; Sanada J; Iwamoto Y; Mashiko A; Horiya M; Mizoguchi-Tomita A; Nishioka M; Kan Y; Kinoshita T; Okauchi S; Hirukawa H; Kohara K; Tatsumi F; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
J Diabetes Res; 2020; 2020():4861681. PubMed ID: 32337293
[TBL] [Abstract][Full Text] [Related]
17. Alternate glycemic markers reflect glycemic variability in continuous glucose monitoring in youth with prediabetes and type 2 diabetes.
Chan CL; Pyle L; Kelsey MM; Newnes L; Baumgartner A; Zeitler PS; Nadeau KJ
Pediatr Diabetes; 2017 Nov; 18(7):629-636. PubMed ID: 27873436
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial.
Abe M; Higuchi T; Moriuchi M; Okamura M; Tei R; Nagura C; Takashima H; Kikuchi F; Tomita H; Okada K
Diabetes Res Clin Pract; 2016 Jun; 116():244-52. PubMed ID: 27321342
[TBL] [Abstract][Full Text] [Related]
19. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
[TBL] [Abstract][Full Text] [Related]
20. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
Min SH; Yoon JH; Hahn S; Cho YM
Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
